Our Vector
(Vtvaf17)
Our Vector in a Nutshell
Introduction:
- Since the beginning of gene therapies, there has been a debate of which vector type is more effective in transporting DNA into a cell. The two main “camps” are: viral and non-viral vectors, each with their advantages & disadvantages (see table left)
- Our value-add: We have taken the non-viral vector approach and attempted to improve it’s main weaknesses. Our vector prioritizes safety and contains four innovative properties:
-
Improved safety of gene therapy due to absence of antibiotic resistance genes
-
Absence of any virus elements in the construction, ensuring further safety
-
Smaller length of vector ensuring a more efficient gene delivery
-
Producibility and constructability on an industrial scale
The Vector Development
Our non-viral DNA vector VTvaf17 has already:
- Filed a separate patent protecting its own IP
- Successfully completed toxicology tests, proving its safety and low side effect risk
- Deposited the strains in an international depository in accordance with Budapest Treaty of 1977
- And is a vehicle that can be used to transport any gene combinations
Strains used for the Vector Development:
- Strain Escherichia coli SCS 110-AF was utilized for the development of the vectors on its base, bearing the section coding the human's target gene(s), and not containing antibiotic resistance genes
- This complies with strict requirements of regulators relating to therapeutic safety of medicinal products
Our Licensing Service: We offer the service of licensing out our vector to third parties at affordable rates. If you are interested in this service please contact us here.